We are assembling a robust portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematologic malignancies. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma.
CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, an EGFR safety switch.
CNTY-103: Our CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
CNTY-103 represents our first clinical product candidate targeting a solid tumor and we believe targeting GBM with our engineered iNK cells may provide opportunity to assess our iPSC-derived iNK cell therapy platform.
CNTY-102: Our CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies.
CNTY-102 will simultaneously target CD19 and CD79b and is designed to increase depth and durability of response by eliminating the effect of CD19 antigen loss while targeting CD79b, an independently regulated, ubiquitous and validated B-cell target.
CNTY-104: Our CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia.
CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML. Given the known therapeutic activity of NK cells in AML, we foresee an advantage to pursuing our iNK platform to develop the product candidate and will plan to evaluate both the iNK and iT platforms for therapeutic benefit.